Why the study?
In patients with left ventricular hypertrophy, reperfusion ventricular fibrillation after cardiopulmonary bypass is more frequent and harder to terminate, but few studies have evaluated whether amiodarone before aortic cross-clamp release reduces VF in this population.
Does prophylactic intravenous amiodarone reduce the incidence of reperfusion ventricular fibrillation in patients with left ventricular hypertrophy undergoing cardiopulmonary bypass surgery?
Does prophylactic intravenous amiodarone reduce the incidence of reperfusion ventricular fibrillation in patients with left ventricular hypertrophy undergoing cardiopulmonary bypass surgery?
This protocol outlines a trial to determine if prophylactic intravenous amiodarone reduces reperfusion ventricular fibrillation in patients with left ventricular hypertrophy undergoing cardiopulmonary bypass.
Planned RCT tests amiodarone for post-ACC VF in LVH; leaves open whether it improves defibrillation success until results reported.
BACKGROUND: Ventricular fibrillation (VF) is a common arrhythmia that occurs after the release of aortic cross-clamp (ACC) in patients undergoing cardiopulmonary bypass (CPB) surgery. Repeated defibrillation and long duration of VF could increase myocardial injuries. In patients with left ventricular hypertrophy (LVH), VF is easier to occur and more difficult to be terminated. Amiodarone, known as class III antiarrhythmic agent, has the prominent properties of converting VF and restoring the sinus rhythm. Before ACC release, administration of amiodarone has been confirmed useful to reduce occurrence of VF. However, few studies are focused on the effect of amiodarone before ACC release on reducing VF in patients with LVH. OBJECTIVE: This study aimed at determining the efficacy of prophylactic intravenous amiodarone administration on reperfusion VF after release of ACC in patients with LVH undergoing CPB surgery. METHODS: This will be a prospective, randomized, double-blind, placebo-controlled trial. The trial will enroll 54 patients with LVH aged 18-75 years who will undergo CPB surgery. All eligible participants will be randomly allocated to either the amiodarone or placebo group by using the block randomization in a 1:1 ratio. The primary end point will be the incidence rate of VF 30 minutes after ACC release and be assessed using the Fisher exact test. All data will be analyzed in accordance with the intention-to-treat principle. RESULTS: The study began in August 2022, and the data collection will take place for the next 2 academic years. As of this writing, 21 participants have already been recruited for the study. CONCLUSIONS: With this trial, we are hoping to demonstrate that prophylactic infusion of amiodarone before ACC release could reduce the occurrence of reperfusion VF in patients with LVH. TRIAL REGISTRATION: ClinicalTrials.gov ChiCTR2000035057; https://www.chictr.org.cn/showprojen.aspx?proj=57145. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/40115.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: